Background and Aim: The purpose of this study was to describe the CT findings of sorafenib-treated hepatic tumors in patients with advanced hepatocellular carcinoma and correlate the findings to the overall survival.
Methods: Sorafenib-treated twenty eight patients with advanced hepatocellular carcinoma with viable hepatic tumors between June 2007 and March 2008 were enrolled. Dynamic CT findings were analyzed with regard to the response of the tumor based on the response evaluation criteria in solid tumor, version 1.1, and the attenuation values of the tumors during the late arterial and portal venous phases. Survival analyses according to early changes of the tumors were also performed.
Results: In all patients, the tumor responses were stable disease or progressive disease on follow-up CT scans. Prior to the treatment, the mean attenuation values of the tumors were 93.0 ± 20.0 HU at the late arterial phase and 107.9 ± 23.0HU at the portal venous phase. On the first follow-up CT scans, the mean attenuation values of the later arterial and portal venous phases were 76.9 ± 26.5 HU and 94.2 ± 29.1 HU, respectively (p < 0.01). The median overall survival was better for the patients with the response of stable disease than the patients with progressive disease (p = 0.013).
Conclusions: In patients with advanced hepatocellular carcinoma who were treated by sorafenib, the size of the hepatic tumors was not significantly reduced. However, the median survival was better for the patients with the response of stable disease. The attenuation values of the tumors became smaller after treatment as compared to the baseline CT scans.